Cytokine profiles and diagnoses in elderly, hospitalized psychiatric patients

Erlend Bugge¹*, Rolf Wynn², Tom Eirik Mollnes³,⁴,⁵,⁶,⁷, Solveig Klaebo Reitan⁸ and Ole Kristian Grønli¹

Abstract

Background: There is a paucity of studies on inflammatory markers in elderly psychiatric patients. Hence, our study was undertaken to investigate cytokines as biomarkers in diagnostically unselected elderly patients admitted to a psychiatric hospital.

Methods: Demographic data, clinical data and blood samples, including 27 cytokines, were collected from 98 patients above 60 years, consecutively admitted to a psychiatric hospital in Tromsø, Norway (69°N).

Results: The most common diagnosis was Recurrent depressive disorder (26.5%), the second most common was dementia in Alzheimer’s disease (20.4%). The most frequent somatic disease was cardiovascular disease (28%). No statistical association \( p < 0.01 \) was found between cytokines and gender, age, BMI, anti-inflammatory drugs, psychotropic drugs, reason for admittance, smoking, vitamin supplements, alcohol consumption, length of stay, somatic disease (present/not-present) or psychiatric diagnoses. However, when allocating patients to two groups, depression and no depression, we found higher levels of 10 cytokines in the no depression group (FDR-\( p < 0.0044 \)). Possibly, this could in part be explained by the higher prevalence of cardiovascular disease (CVD) and dementia in the no depression group, as these factors were significant predictors of patients being categorized as not depressed in a logistic regression. In addition, other unknown factors might have contributed to the association between no depression and elevated cytokines. On the other hand, the high level of psychiatric and somatic comorbidity in the study population may have led to increased levels of cytokines in general, possibly diluting the potential effect of other factors, depression included, on the cytokine levels.

Conclusions: There was no significant difference in cytokine levels between various psychiatric diagnoses in hospitalized elderly psychiatric patients. This indicates that previous findings of correlations between cytokines and various psychiatric disorders in highly selected adult cases might not be applicable to elderly psychiatric inpatients. Further immunological studies are needed on gerontopsychiatric patients in general and gerontopsychiatric patients with specific disorders, preferably with patients that are physically healthy.

Trial registration: Retrospectively registered in the ISRCTN registry study, with study ID ISRCTN71047363.

Keywords: Psychogeriatric, Gerontopsychiatric, Cytokine, Depression, Neuroimmunology

* Correspondence: erlend.bugge@unn.no
¹Division of Mental Health and Addictions, University Hospital of North Norway, N-9037 Tromsø, Norway
Full list of author information is available at the end of the article

© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Several studies have demonstrated an association between psychiatric disorders and biomarkers of inflammation, particularly cytokines. Primarily, these studies have focused on specific disorders and selected sets of cytokines. Depression and schizophrenia seem to dominate this research, both disorders repeatedly demonstrating elevated levels of pro-inflammatory cytokines such as IL-1β, IL-2, IL-6, and TNF [1–3]. Though some of these studies include elderly patients [4–6], most studies have been conducted on younger adults. Thus, there is a paucity of studies on elderly psychiatric patients and particularly elderly psychiatric in-patients. Besides the fact that populations are ageing in most countries [7], the elderly are of particular interest because they are more likely to represent biological diversity due to age-related neuroimmunological changes [8] and higher frequencies of comorbid conditions. Consequently, findings of cytokine changes in younger adults do not readily translate to elderly psychiatric patients. Hence, our study was undertaken to investigate cytokines as biomarkers in diagnostically unselected elderly patients admitted to a psychiatric hospital.

Methods
Population
The population has been described in a previous publication [9]. Demographic data, clinical data and blood samples were collected from 98 patients, 60 years and older, consecutively admitted to a psychiatric hospital in Tromsø, Norway (69°N). The catchment area of the hospital was approximately 250,000 citizens. Exclusion criteria comprised inability to communicate and cooperate, e.g. due to a severe psychiatric condition like severe dementia or confusion/delirium, or a medical condition likely to significantly affect the blood/plasma analysis like severe dehydration or ongoing infection. The reasons for referral included a variety of psychiatric conditions, spanning from anxiety to psychosis, with depression (42%) and dementia (26%) being the most common. In terms of gender, age and diagnostic distribution, the study population was quite similar to the general population of patients admitted to gerontopsychiatric units in Norway [10], the possible exception being a lower proportion of dementia. However, the Norwegian national data included patients with severe dementia, whereas these patients were excluded from our study.

Clinical assessment
The following instruments were applied to assess the psychiatric and cognitive status of the participants (N = number of patients): the MINI International Neuropsychiatric Interview, N = 43 [11], the Montgomery and Aasberg Depression Rating Scale, N = 76 [12], the Cornell Scale for Depression in Dementia, N = 22 [13], the Mini-Mental State Examination, N = 92 [14] and the Clockdrawing Test, N = 90 [15]. In addition, clinical interviews and reviews of medical records were undertaken by experienced clinicians in assessment and diagnostics, according to ICD-10 research criteria. Interview of next of kin was also undertaken when appropriate.

Blood samples
During the first 3 days of admittance, morning blood samples (before 10 AM) were obtained for a range of analyses, e.g. electrolytes, liver enzymes, blood cells and thyroid hormones. In addition, plasma samples from EDTA-tubes were successively and rapidly frozen to −70 °C, until analysed for cytokines in one batch. The analyses were performed by multiplex technology on a Multiplex Analyser with a predefined kit, according to the instructions of the manufacturer (Bio-Plex Human Cytokine 27-Plex Panel; Bio-Rad Laboratories Inc., Hercules, CA, USA). The assay was set up to detect the following interleukins, chemokines and growth factors: IL-1β, IL-1 receptor antagonist (IL1-ra), IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12 (p70), IL-13, IL-15, IL-17, eotaxin, basic fibroblast growth factor (bFGF), granulocyte-colony stimulating factor (G-CSF), granulocyte macrophage colony stimulating factor (GM-CSF), interferon (IFN)-γ, interferon-inducible protein (IP-10), monocyte chemotactic protein (MCP-1), macrophage inflammatory protein (MIP-1α, MIP-1β), platelet derived growth factor-BB (PDGF-BB), regulated upon activation T cell expressed and secreted (RANTES), tumor necrosis factor (TNF), and vascular endothelial growth factor (VEGF).

GM-CSF and IL-15 had a high frequency of non-detectable levels, i.e. below the lower detection limit, and were therefore excluded in the statistical analyses. Another eight cytokines had a small number of patients with cytokine levels below the lower detection limit (number of patients with non-detectable levels): IL-2 (4), IL-10 (11), IL-13 (1), IL-17 (4), bFGF (2), G-CSF (2), PDGF-BB (2), and VEGF (4). Data for these patients were imputed using SPSS, see Statistical analyses section.

Statistical analyses
Most of the data were not strictly normally distributed, as demonstrated by the Kolmogorov-Smirnov test, and several groups had unequal variances. Thus, nonparametric tests were applied. The Spearman rank correlation coefficient and Kendall Tau coefficient were used to analyse differences between the rankings of two variables. The Mann-Whitney U or the Kruskal-Wallis tests were applied when comparing ranks of two or several
subgroups, subsequently. Goodness of fit was assessed by binary logistic regression. To examine whether the raised cytokine levels and the other variables could predict depression, we performed logistic regression analyses with depression/no depression as dependent variable. Patients were allocated to the depression group if they had been given depression as a primary or secondary diagnosis, or the no depression group if they had not been given a depression analysis.

Due to multiple statistical analyses, 0.01 was selected as significance level. In addition, false detection rate adjusted p-value (FDR-p) was calculated and applied to all analyses related to the cytokines. IBM Statistical Package for the Social Sciences, Version 23 (SPSS Inc., Chicago, Illinois, USA) software was used in the statistical analysis.

A small group of patients had no or very low levels of certain cytokines (which is a common finding for most cytokines in healthy adults), but the actual value could not be computed by the instrumentation; they are so-called non-detects (NDs). Accordingly, data from the NDs could hold valuable information, and in order to include them in the statistical analyses, we did single imputations, i.e. the NDs were substituted with a random value between zero and the lower detection limit, with a uniform distribution, using the random number generator of SPSS [16].

Results

Population characteristics
Population characteristics are presented in Table 1.

Diagnoses
The main diagnostic groups are presented in Table 2. The most common diagnosis was Recurrent depressive disorder (26.5%), the second most common was dementia in Alzheimer’s disease (20.4%). Considering depression as a separate clinical entity, depending on whether the patients had been given depression as a primary or secondary diagnosis or not, the majority of patients could be allotted to the depression group, see Table 2. Selected features of the groups depression and no depression are presented in Table 3.

Distribution and correlation analysis
The cytokine values of the patients are presented in Table 4. In this group of diagnostically unselected elderly in-patients, no statistical correlation or unequal distribution was found between cytokines and gender, age, BMI, anti-inflammatory drugs, psychotropic drugs, reason for admittance, smoking, vitamin supplements, alcohol consumption, length of stay, somatic disease (present/not-present) or psychiatric diagnoses, dementia included. However, a correlation (FDR-p < 0.0044) was found between no depression (N = 39) and raised levels of several cytokines, see Table 5.

While none of the raised cytokine levels predicted depression in a logistic regression model, cardiovascular disease (CVD) and dementia were predictors of patients being categorized as not depressed/no depression (Table 6). However, none of the cytokines came out as predictive in logistic regression models with CVD/no CVD, or dementia/no dementia, as dependent variables.

Looking at distributional data, CVD and dementia were more prevalent in the no depression group, compared to the depression group, 46.2% versus 15.3%, and 51.3% versus 22.0%, respectively.

| Characteristic                  | Value      |
|--------------------------------|------------|
| Age, median/SD (years)         | 76/7.3     |
| 80 years and older (%)         | 39.8       |
| Women (%)                      | 61.2       |
| Men (%)                        | 38.8       |
| Length of stay, median/SD (days)| 34/25      |
| Living alone (%)               | 53         |
| Previous hospitalization (%)   | 49         |
| Two or more previous hospitalizations (%) | 38 |
| No known somatic disease (%)   | 21         |
| Cardiovascular disease (%)     | 28         |
| Pulmonary disease (%)          | 10         |
| Thyroid disease (%)            | 10         |
| Previous stroke (%)            | 10         |
| Rheumatic disease (%)          | 3.5        |
| Other somatic diseases (%)     | 17.5       |
| Potentially anti-inflammatory drug (%) | 55.1 |
| Daily smokers (%)              | 29.6       |
| BMI, median/SD (kilos)         | 24/5.3     |

Table 1  In-patients’ characteristics

| Diagnoses                              | ICD-10 | %    |
|----------------------------------------|--------|------|
| Organic, including symptomatic, mental disorders | F00–09 | 37.8 |
| Mental and behavioural disorders due to psychoactive substance abuse | F10–19 | 1    |
| Schizophrenia, schizotypal and delusional disorders | F20–29 | 12.2 |
| Affective disorders                    | F30–39 | 41.8 |
| Neurotic, stress-related and somatoform disorders | F40–48 | 7.2  |
| Depression/No depression               |        | 60.2/39.8 |

*Psychiatric hospitalization
b The most common drug in this category is acetylsalicylic acid in low dose as prevention of cardiovascular events (N = 30/68.2%)
Discussion
To our knowledge, this is the first study to explore cytokine levels in diagnostically unselected elderly psychiatric in-patients. Using an immunoassay method, we analysed 27 plasma cytokines in 98 patients, 60 years and older, admitted to a gerontopsychiatric unit.

The results demonstrated that cytokine levels did not correlate with variables such as age, gender, psychiatric diagnoses, somatic disease (present/not present), and the use of anti-inflammatory and psychotropic drugs. Considering each of these factors separately, this does not seem to match previous findings, as prior studies have shown positive associations between for instance Alzheimer's disease and increased levels of several cytokines [17], and between aging and increased levels of IL-6 and TNF-α [18]. Then again, our heterogeneous study population differs substantially from most of the diagnostically uniform populations previously studied.

The high frequency of somatic and psychiatric comorbidity in the study population may have contributed to the increased levels of cytokines in general, masking possible correlations between any single factor and changes in levels of cytokines. On the other hand, there is a possibility that altered immune activity in psychiatric patients is a general phenomenon, not restricted to specific diagnoses. Such a hypothesis can be bolstered by the fact that research has shown raised levels of inflammatory markers in several psychiatric disorders, ranging from schizophrenia to anxiety disorders [19, 20].

Contrary to some prior studies, we did not find any correlation between cytokines and depression. Given the fact the majority of our depressed patients were diagnosed with recurrent depressive disorder, it could be

Table 3 Selected features of depressed and non-depressed patients

| Comorbidity/feature     | Depression (%) | No depression (%) |
|-------------------------|----------------|------------------|
| Somatic disease (any)   | 76.3           | 82.1             |
| Cardiovascular disease  | 15.3           | 46.2             |
| Dementia                | 22.0           | 51.3             |
| Antidepressants         | 74.6           | 25.6             |

Table 4 Serum levels of cytokines (pg/ml) in elderly psychiatric in-patients

| Cytokine | Median | SD** | Minimum | Maximum | P 25*** | P 75*** |
|----------|--------|------|---------|---------|---------|---------|
| IL-1b    | 3.00   | 4.65 | 0.53    | 38.00   | 1.58    | 5.00    |
| IL-1ra   | 158.00 | 769.64 | 31.00   | 7396.00 | 84.00 | 268.75 |
| IL-2     | 9.00   | 17.97 | 0.01    | 147.00  | 3.00    | 16.00   |
| IL-4     | 3.00   | 2.55  | 1.00    | 13.00   | 2.00    | 4.00    |
| IL-5     | 5.00   | 5.65  | 0.73    | 28.00   | 3.00    | 9.00    |
| IL-6     | 11.00  | 15.39 | 3.00    | 119.00  | 7.00    | 18.75   |
| IL-7     | 21.00  | 22.83 | 0.25    | 104.00  | 11.00   | 36.00   |
| IL-8     | 13.00  | 9.35  | 3.00    | 47.00   | 8.00    | 19.00   |
| IL-9     | 18.00  | 47.03 | 3.00    | 441.00  | 11.00   | 28.00   |
| IL-10    | 8.50   | 16.92 | 0.01    | 102.00  | 2.00    | 16.00   |
| IL-12    | 27.00  | 51.60 | 0.05    | 381.00  | 11.00   | 46.75   |
| IL-13    | 7.00   | 15.51 | 0.50    | 96.00   | 4.00    | 14.00   |
| IL-17    | 42.50  | 66.57 | 0.35    | 371.00  | 15.25   | 88.25   |
| Eotaxin  | 93.00  | 257.20 | 28.00   | 2286.00 | 65.50 | 157.75 |
| bFGF     | 46.00  | 48.58 | 1.16    | 579.00  | 21.00   | 79.75   |
| G-CSF    | 52.00  | 52.92 | 1.53    | 316.00  | 29.25   | 82.75   |
| INF-g    | 184.00 | 217.26 | 20.00   | 1179.00 | 94.75 | 280.75 |
| IP-10    | 1015.50 | 744.58 | 216.00 | 5075.00 | 762.25 | 1338.00 |
| MCP-1    | 19.00  | 16.04 | 4.00    | 128.00  | 13.25   | 26.00   |
| MIP-1a   | 10.00  | 9.82  | 2.00    | 58.00   | 6.00    | 15.00   |
| MIP-1b   | 44.00  | 24.77 | 17.00   | 198.00  | 34.00   | 56.00   |
| PDGF-BB  | 137.50 | 325.59 | 1.03    | 1651.00 | 34.25 | 308.00 |
| RANTES   | 6642.00 | 12,393.18 | 532.00 | 60,319.70 | 2876.00 | 16,859.75 |
| TNF-a    | 92.00  | 137.85 | 8.00    | 1173.00 | 43.50   | 127.25  |
| VEGF     | 21.50  | 25.94 | 1.90    | 130.00  | 10.00   | 36.00   |

* Standard deviation. ** 25-percentile. *** 75-percentile
hypothesized that relapsing depression in the elderly represents a somewhat different immunological process compared to depression in younger patients, on whom most studies have been conducted. On the other hand, our intra-group comparison could be the main explanation why the depressed patients did not have comparably higher levels of cytokines, considering that the overall level of cytokines was high regardless of diagnosis.

One relevant point to consider is that anti-depressants have exhibited anti-inflammatory properties in both clinical and experimental studies [21, 22]. Accordingly, the high percentage of antidepressant use in the depression group (74.6% versus 25.6% in the no depression group) might have been a factor in terms of lowering the cytokine levels amongst the depressed patients, cancelling out the association between depression and cytokine levels.

We did observe a correlation between no depression, a term denoting patients without significant depression irrespective of other clinical features, and several cytokines (FDR-<i>p</i> < 0.0044). Presumably, this correlation is not explained by the lack of depression per se. Rather, it is more likely that other factors contribute to increased cytokines in the no depression group. CVD and dementia are two possible contributing factors, as they are more prevalent in the no depression group, hence becoming predictors in a binary logistic model. Both CVD and dementia have been linked to increased levels of cytokines [23–26]. Yet, the fact that none of the cytokines correlated with dementia or CVD, in addition to the absence of predictive power of any of the cytokines for both dementia and CVD in binary logistic regression, indicate that other, unrecognized factors also contribute to the association between no depression and elevated cytokines.

Finally, it should be taken into account that the total level of psychiatric morbidity in the no depression group (e.g. organic mental disorders) was probably just as high, perhaps higher, than in the depression group, hence diluting the potential effect of depression on the cytokine levels. There might also be a proportion of the no depression patients with dementia that actually was depressed, as it cannot be ruled out that patients with dementia express depressive symptoms in a way that is less likely to be recognized by the clinician. Then again, altered cytokine levels in psychiatric patients

**Table 5** Correlation between cytokines and No depression (<i>p</i>-level > 0.01 excluded)

| Cytokine | Correlation coefficient* | <i>p</i> | FDR-i** | Significant*** | Eta**** |
|----------|--------------------------|--------|---------|----------------|--------|
| IL-2     | 0.268                    | 0.008  | 0.0060  | No             | 0.072  |
| bFGF     | 0.271                    | 0.008  | 0.0056  | No             | 0.074  |
| IL-1ra   | 0.271                    | 0.008  | 0.0052  | No             | 0.074  |
| IL-1b    | 0.283                    | 0.005  | 0.0048  | No             | 0.080  |
| IL-5     | 0.288                    | 0.004  | 0.0044  | Yes            | 0.083  |
| IL-12    | 0.289                    | 0.004  | 0.0040  | Yes            | 0.083  |
| IL-6     | 0.290                    | 0.004  | 0.0036  | Yes            | 0.084  |
| TNF-a    | 0.295                    | 0.004  | 0.0028  | Yes            | 0.087  |
| IL-7     | 0.306                    | 0.002  | 0.0024  | Yes            | 0.093  |
| IL-10    | 0.321                    | 0.001  | 0.0020  | Yes            | 0.103  |
| G-CSF    | 0.322                    | 0.001  | 0.0016  | Yes            | 0.104  |
| INF-g    | 0.334                    | 0.001  | 0.0012  | Yes            | 0.111  |
| IL-4     | 0.348                    | 0.001  | 0.0008  | Yes            | 0.121  |
| IL-8     | 0.349                    | 0.000  | 0.0004  | Yes            | 0.122  |

* Spearman Rho; **False detection rate adjusted <i>p</i>-value, q-level 0.01, based on <i>p</i>-values of all 25 cytokines; ***FDR-adjusted <i>p</i>-criterion of 0.0044; ****Effect size.

Based on Mann-Whitney Z-statistics of all 25 cytokines

**Table 6** Logistic regression model assessing predictors of patients categorized as no depression

| Predictors of no depression | Log odds | SE** | Wald Chi² | P-value | Odds ratio | 95% CI for OR Lower - Upper |
|-----------------------------|---------|------|-----------|---------|------------|-----------------------------|
| Dementia (<i>N</i> = 20)    | 1.422   | 0.484| 8.651     | 0.003   | 4.147      | 1.607–10.700                |
| Cardiovascular disease (<i>N</i> = 18) | 1.664 | 0.515| 10.441    | 0.001   | 5.279      | 1.924–14.479                |
| Constant                   | -1.409  | 0.344| 16.745    | 0.000   | 0.244      |                             |

*Nagelkerke R Square 0.253, Cox & Snell R Square 0.187
**SE: Standard error
***CI: Confidence interval
may be a general phenomenon, possibly being primarily dependent on the severity of the disorder, and not the diagnosis.

When interpreting the result of our study, we need to be cautious, given the size of the study, and particularly the size of the subgroups. It should also be noted that though we chose 0.01 as significance levels due to multiple comparisons, and calculated FDR-p for the cytokine statistics, the risk of spurious correlations is still present. On this point, it worth mentioning that a Bonferroni correction would have required a significance threshold of 0.002. Moreover, applying few exclusion criteria may have provided a study population that resembled real-life gerontopsychiatric in-patients, but heightened the risk of confounders due to the general heterogeneity of the group, i.e. differences in age, socioeconomic background, lifestyle factors etc. Adding to this risk was the possibility of greater variability in health status, including immunological functioning, in the elderly compared to younger adults. Another possible source of cytokine variability could be that not all blood samples were fasting (35.7% non-fasting). Though the studies are somewhat conflicting, most seem to indicate that fasting has a certain anti-inflammatory effect [27–29]. A correlational analysis between fasting and cytokine levels in our population demonstrated nevertheless no correlation. Furthermore, a control group of healthy elderly would have made a statistical comparison possible, but at the time, we did not have such data available. Finally, it should be mentioned that single imputation of data to remedy NDs (see section Statistical analysis) may confer a risk of distorting the statistics, in particular when the number of NDs are high. In our study, the number of NDs are small (four at the most) and running the statistics without the NDs did not produce any significant change.

The plasma levels of cytokines observed in this group of elderly patients were the results of complex immunological processes, where different cytokines might have played different roles at different stages. Several interacting factors, such as age, life style factors, somatic health, genetics, drugs and the psychiatric disorders per se, may have contributed in these processes. Besides, it is still unclear how an increased level of cytokines in systemic circulation relates to neuroimmunological processes in psychiatric disorders. Adding to the complexity is the application of various methods of cytokine analysis and methodological issues [30, 31]. Hence, caution should be exercised when interpreting data and making inferences about cytokine profiles and biomarkers in psychiatry, and perhaps particularly in the elderly population. This also begs the question as to what extent findings in younger adults, with uniform diagnostic profiles and no comorbidity, have bearings on real-life elderly patients.

Though the field of old age neuroimmunology has made great advances in the last decade, there is still a lot to be learned about the immunology of gerontopsychiatry. Further studies are needed on gerontopsychiatric patients in general and gerontopsychiatric patients with specific disorders, preferably with patients that are physically healthy. Clinical studies are necessary to gauge the immunological effects, both cellular and humoral, of various forms of treatment. As for our patients, the question is if psychiatric treatment can impact the high, probably multi-etiological, levels of cytokines. Finally, genomic and proteomic studies are required to uncover the immunological underpinnings of psychiatric disorders affecting the elderly, including longitudinal studies of healthy populations at risk.

Conclusions
There was no significant difference in cytokine levels between various psychiatric diagnoses in elderly psychiatric in-patients. However, when patients were allocated to two groups, depression and no depression, irrespective of diagnoses and other clinical features, we found higher levels of certain cytokines in the no depression group compared to the depression group. This might be due to a higher frequency of CVD and dementia in the no depression group, as well as other unknown factors.

Abbreviations
BMI: Body mass index; CVD: Cardiovascular disease; EDTA: Ethylenediaminetetraacetic acid; FDR: False detection rate; ICD-10: International classification of diseases version 10; NDs: Non-detects; SPSS: Statistical package for the Social Sciences

Acknowledgments
We thank the laboratory staff at the Department of Laboratory Medicine, University Hospital of North Norway for their contributions to this study. We also thank the participating patients.

Funding
This project is financed by the Northern Norway Regional Health Authority, grant number PFP1298–16. The recipients are EB and OKG. The funding institution had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The publication charges for this article have been funded by a grant from the publication fund of UiT The Arctic University of Norway.

Availability of data and materials
The dataset used during the current study is available in from the corresponding author upon reasonable request.

Authors’ contributions
EB designed the study, analyzed the data, drafted the manuscript, revised the manuscript, and approved the final version. OKG designed the study, analyzed the data, drafted the manuscript, revised the manuscript, and approved the final version. RW designed the study, analyzed the data, drafted the manuscript, revised the manuscript, and approved the final version. SKR analyzed the data, drafted the manuscript, revised the manuscript, and approved the final version. All authors have agreed to be accountable for all
aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

**Ethics approval and consent to participate**

Oral and written information about the study were presented to all eligible patients. Competency to provide consent was assessed according to established guidelines [32]. For those patients who were considered unable to give individual consent due to their medical condition, information about the study was provided to their next of kin. All patients, and their next of kin when relevant, had to sign a written consent in order to participate in the study. Approval of the study was obtained from the Regional Committee for Medical and Health Research Ethics of Northern Norway (REC North, reg. nr. 2009/I138).

**Consent for publication**
Not applicable.

**Competing interests**

The authors declare that they have no competing interests.

**Publisher’s Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Author details**

1. Division of Mental Health and Addictions, University Hospital of North Norway, N-9037 Tromsø, Norway.
2. Department of Clinical Medicine, UiT The Arctic University of Norway, N-9038 Tromsø, Norway.
3. Centre of Molecular Inflammation Research, Norwegian University of Science and Technology, Faculty of Medicine and Health Sciences, N-7491 Trondheim, Norway.
4. Research Laboratory, Nordland Hospital, Bodø, Norway.
5. Faculty of Health Sciences, K.G. Jebsen TREC, N-9038 Tromsø, Norway.
6. Department of Immunology, Oslo University Hospital, and University of Oslo, Oslo, Norway.
7. Norwegian University of Science and Technology, Faculty of Medicine and Health Sciences, N-7491 Trondheim, Norway.
8. Norwegian University of Arctic University of Norway, K.G. Jebsen TREC, N-9038 Tromsø, Norway.
9. Research Laboratory, Nordland Hospital, Bodø, Norway.
10. Department of Medicine, Faculty of Medicine and Health Sciences, UiT, The Arctic University of Norway, Tromsø, Norway.
11. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59(Suppl 20):22–33 quiz 4–5. 12. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382–9.
13. Alexopoulos GS, Abrams RC, Young RC, Shamian CA. Cornell scale for depression in dementia. Biol Psychiatry. 1988;29(3):271–84.
14. Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189–98.
15. Tuokko H, Hadjistavlopoulos T, Miller JA, Beattie BL. The clock test: a sensitive measure to differentiate normal elderly from those with Alzheimer disease. J Am Geriatr Soc. 1992;40(6):579–84.
16. Ut HWHF, Yazdanbakhsh M, Howling-Duistermaat JJ. Evaluation of regression methods when immunological measurements are constrained by detection limits. BMC Immunol. 2008;8:59.
17. Hepper FL, Ransohoff RM, Becher B. Immune attack: the role of inflammation in Alzheimer disease. Nat Rev Neurosci. 2015;16(6):358–72.
18. Singh T, Newman AB. Inflammatory markers in population studies of aging. Ageing Res Rev. 2011;10(3):270–9.
19. Vogelzangs N, Beekman AT, de Jonge P, Penninx BW. Anxiety disorders and inflammation in a large adult cohort. Transl Psychiatry. 2013;3:e249.
20. Rodrigues-Amorim D, Rivera-Baltanas T, Spuch C, Caruncho HJ, Gonzalez-Fernandez A, Olivares JM, et al. Cytokines dysregulation in schizophrenia: A systematic review of psychoneuroimmune relationship. Schizophr Res. 2017.
21. Hashioka S, Miyoka T, Wake R, Furuya M, Horiguchi J. Glia: an important target for anti-inflammatory and antidepressant activity. Curr Drug Targets. 2013;14(11):1322–8.
22. Hashioka S, McGeer PL, Morji A, Kanba S. Anti-inflammatory effects of antidepressants: possibilities for preventives against Alzheimer’s disease. Curr Nerv Syst Agents Med Chem. 2009;9(1):1–9.
23. Kapteyn S, Sehajpal SR, Gao P, Freitag DF, Burteworth AS, Borjylkke A, et al. Inflammatory cytokines and risk of coronary heart disease: new prospective study and updated meta-analysis. Eur Heart J. 2014;35(9):578–89.
24. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352(16):1685–95.
25. Clough Z, Jeyapal P, Zotova E, Holmes C. Proinflammatory cytokines and the clinical features of dementia with Lewy bodies. Alzheimer Dis Assoc Disord. 2015;29(1):197–9.
26. Angelopoulos P, Agouridaki H, Vaipopoulos H, Siskou E, Doutsou K, Costa V, et al. Cytokines in Alzheimer’s disease and vascular dementia. Int J Neurosci. 2008;118(12):1659–72.
27. Trab J, Geiger SS, Kwasteng-Saw M, Han K, Ra OH, Siegel RM, et al. Prolonged fasting suppresses mitochondrial NLRP3 inflammasome assembly and activation via SIRT3-mediated activation of superoxide dismutase 2. J Biol Chem. 2017;292(29):21535–64.
28. Faris MA, Kacimi S, Al-Kurd RA, Fararjeh MA, Bustanji YK, Mohammad MK, et al. Intermittent fasting during Ramadan attenuates proinflammatory cytokines and immune cells in healthy subjects. Nutr Res. 2012;32(12):947–55.
29. Aliashfari F, Izadi A, Gargari BP, Ebshimi S. The effects of Ramadan fasting on body composition, blood pressure, glucose metabolism, and markers of inflammation in NAFLD patients: an observational trial. J Am Coll Nutr. 2017;36(6):640–5.
30. Zhou X, Fragala MS, McElhaney JE, Kuchel GA. Conceptual and methodological issues relevant to cytokine and inflammatory marker measurements in clinical research. Curr Opin Clin Nutr Metab Care. 2010;13(5):541–7.
31. Biancotto A, Wank A, Perl S, Cook W, Olness MJ, Dagur PK, et al. Baseline levels and temporal stability of 27 multiplexed serum cytokine concentrations in healthy subjects. PLoS One. 2013;8(12):e76091.
32. Pedersen R, Hofmann B, Mangset M. Patient autonomy and informed consent in clinical practice. Tidsskr Nor Laegeforen. 2007;127(12):1644–7.